The completion of enrollment and transition to follow-up reduces near-term cash burn but provides no new catalyst on its own. Monitor for RMAT designation update, Phase 3 meeting outcomes, and follow-up data releases.
Price Chart
Executive Summary
Creative Medical Technology announced that all patients have been enrolled and treated across its ADAPT clinical trial for Olastrocel (CELZ-201) in chronic lower back pain, including an opioid expansion cohort. The program now transitions to follow-up and regulatory preparation, with management expecting reduced near-term trial costs to preserve capital and extend operating runway without an immediate need for fundraising. This is a clinical milestone update with no new definitive efficacy or safety results beyond previously disclosed interim data.
Key Facts
- All patients enrolled and treated across original and FDA-cleared opioid expansion cohorts of the ADAPT trial.
- DSMB previously confirmed favorable safety profile with no significant adverse events.
- Interim 180-day data: mean ODI% improvement of -15.3 percentage points; ~79% of patients achieved clinically meaningful functional improvement.
- Mean pain reduction of -3.9 points on 0-10 scale at 180 days; ~79% achieved ≥2-point reduction.
- Management expects ADAPT-related enrollment and treatment costs to decrease, helping preserve capital and extend operating runway.
- Company plans to pursue RMAT evaluation and Phase 3 discussions with FDA.
- CELZ market cap ~$7M; pre-revenue clinical-stage biotech.
Financial Impact
No financial data reported; company is pre-revenue. Cost reduction from completed enrollment expected to preserve capital, but no dollar figures provided.
Risk Factors
- No new efficacy or safety data released; interim data already disclosed.
- Olastrocel remains investigational; FDA approval not guaranteed.
- Limited operating runway; no fundraising detail provided.
- Pre-revenue, clinical-stage biotechnology with binary trial risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3348448 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | SC 13D | $0.9464 $0.9200 | ▼ −2.79% | ▼ −3.46% | $0.7120 (−24.77%) |
Sep 25, 2026 4w ago | 8-K | $1.01 $0.9652 | ▼ −4.44% | ▼ −4.25% | $0.7120 (−29.50%) |
Sep 17, 2026 5w ago | Press Release | $0.8775 $0.9659 | ▲ +10.07% | ▲ +10.19% | $0.7120 (−18.86%) |
Aug 20, 2026 9w ago | Press Release | $1.28 $1.31 | ▲ +2.34% | ▲ +1.93% | $0.7120 (−44.37%) |
Jul 1, 2026 16w ago | Press Release | $1.27 $1.21 | ▼ −4.72% | ▼ −4.59% | $0.7120 (−43.94%) |
Jun 30, 2026 16w ago | Press Release | $1.45 $1.27 | ▲ +12.41% | ▲ +12.28% | $0.7120 (+50.90%) |
Jun 26, 2026 17w ago | S-1/A | $0.8102 $1.45 | ▼ −78.97% | ▼ −78.19% | $0.7120 (+12.12%) |
Jun 25, 2026 17w ago | S-1 | $1.20 $0.8102 | ▼ −32.48% | ▼ −34.13% | $0.7120 (−40.67%) |
Jun 22, 2026 18w ago | Press Release | $1.93 $1.97 | ▲ +2.07% | ▲ +3.52% | $0.7120 (−63.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers